Theriva Biologics, Inc. announced the outcomes of a Type D meeting with the FDA regarding the design of a Phase 3 clinical study for their drug VCN-01, confirming the need for a stand-alone study without additional chemotherapy. They also completed target enrollment for a Phase 2b study evaluating VCN-01 with gemcitabine/nab-paclitaxel for pancreatic cancer patients.